A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report

Igaue,Shota; Okuno,Takayuki; Ishibashi,Hajime; Nemoto,Masaru; Hiyoshi,Masaya; Kawasaki,Hiroshi; Saitoh,Hitoaki; Saitoh,Makoto; Akagi,Kiwamu; Yamamoto,Junji

doi:10.3892/ol.2022.13332

A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair‑deficient/microsatellite instability‑high metastatic colon cancer: A case report

Authors:
- Shota Igaue
- Takayuki Okuno
- Hajime Ishibashi
- Masaru Nemoto
- Masaya Hiyoshi
- Hiroshi Kawasaki
- Hitoaki Saitoh
- Makoto Saitoh
- Kiwamu Akagi
- Junji Yamamoto
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Department of Gastroenterology, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Department of Pathology, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Center for Clinical Genetics and Genomics, Ibaraki Cancer Center, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Kitaadachi‑gun, Saitama 362‑0806, Japan
Published online on: May 17, 2022 https://doi.org/10.3892/ol.2022.13332
Article Number: 211
Copyright: © Igaue et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The standard treatment for colorectal cancer has always been surgery and chemotherapy, which may be used in combination to treat patients. Immune checkpoint inhibitors have been a significant advancement in the standard treatment of metastatic, unresectable colorectal cancer with deficient mismatch repair. However, little information is available about their use in neoadjuvant and conversion settings with only a few case reports and only one phase 2 trial. The present study reports the case of a large, locally advanced right‑sided metastatic deficient mismatch repair/microsatellite instability‑high colon cancer, which showed a pathological complete response after combination treatment with nivolumab and ipilimumab. To the best of our knowledge, resected metastatic colon cancer with a pathological complete response after treatment using dual immune checkpoint inhibitors has not been previously reported. Overall, this case report suggests the use of immune checkpoint inhibitors before colorectal surgery.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
3	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar
4	van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R and Verhoef C: Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: A population-based series. Colorectal Dis. 14:56–61. 2012. View Article : Google Scholar : PubMed/NCBI
5	Fakih MG: Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 33:1809–1824. 2015. View Article : Google Scholar
6	Akagi K, Oki E, Taniguchi H, Nakatani K, Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 112:1105–1113. 2021. View Article : Google Scholar
7	Lumish MA and Cercek A: Immunotherapy for the treatment of colorectal cancer. J Surg Oncol. 123:760–774. 2021. View Article : Google Scholar
8	André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar
9	Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018. View Article : Google Scholar
10	Seymour MT and Morton D: FOxTROT: An international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 37 (Suppl 15):S35042019. View Article : Google Scholar
11	Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, et al: The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 161:584–591. 2017. View Article : Google Scholar : PubMed/NCBI
12	Krishnamoorthy M, Lenehan JG and Maleki Vareki S: Neoadjuvant immunotherapy for high-risk, resectable malignancies: Scientific rationale and clinical challenges. J Natl Cancer Inst. 113:823–832. 2021. View Article : Google Scholar
13	Lee AY and Brady MS: Neoadjuvant immunotherapy for melanoma. J Surg Oncol. 123:782–788. 2021. View Article : Google Scholar
14	Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 25:477–486. 2019. View Article : Google Scholar : PubMed/NCBI
15	Jia XH, Xu H, Geng LY, Jiao M, Wang WJ, Jiang LL and Guo H: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis. Lung Cancer. 147:143–153. 2020. View Article : Google Scholar : PubMed/NCBI
16	Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, et al: Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 26:566–576. 2020. View Article : Google Scholar : PubMed/NCBI
17	Kinney RE and Khalil M: Neoadjuvant immunotherapy in microsatellite-instability high nonmetastatic colorectal cancer: A single-institute experience and review of the literature. Clin Colorectal Cancer. 20:e109–e112. 2020. View Article : Google Scholar : PubMed/NCBI
18	Tomasello G, Petrelli F, Ghidini M, Russo A, Passalacqua R and Barni S: FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: A systematic review and pooled analysis. JAMA Oncol. 3:e1702782017. View Article : Google Scholar
19	Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D and Adam R: Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: The OLIVIA multinational randomised phase II trial. Ann Oncol. 26:702–708. 2015. View Article : Google Scholar
20	Hu H, Wang K, Huang M, Kang L, Wang W, Wang H, Qiu M, Lin R, Zhang H, Lan P, et al: Modified FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM multicenter phase II trial. Oncologist. 26:e90–e98. 2021. View Article : Google Scholar
21	Yang J, Bi F and Gou H: Complete pathologic response after concurrent treatment with pembrolizumab and radiotherapy in metastatic colorectal cancer: A case report. Onco Targets Ther. 14:2555–2561. 2021. View Article : Google Scholar : PubMed/NCBI
22	Curran MA, Montalvo W, Yagita H and Allison JP: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280. 2010. View Article : Google Scholar : PubMed/NCBI
23	Sharma P and Allison JP: The future of immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
24	Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 372:2006–2017. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 15:7412–7420. 2009. View Article : Google Scholar : PubMed/NCBI
26	Colle R, Radzik A, Cohen R, Pellat A, Lopez-Tabada D, Cachanado M, Duval A, Svrcek M, Menu Y and André T: Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer. 144:9–16. 2021. View Article : Google Scholar : PubMed/NCBI
27	Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M and Wildgruber M: The beginning of the end for conventional RECIST-novel therapies require novel imaging approaches. Nat Rev Clin Oncol. 16:442–458. 2019. View Article : Google Scholar
28	Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U and Glas M: Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro Oncol. 18:1462–1464. 2016. View Article : Google Scholar
29	Ma Y, Wang Q, Dong Q, Zhan L and Zhang J: How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 9:1546–1553. 2019.PubMed/NCBI